Glenmark Pharma secures European approval for Ryaltris nasal spray to treat allergic rhinitis

Glenmark has received an upfront payment and will additionally receive launch & sales based milestone payments from Menarini for Ryaltris sales.

Ryaltris, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals, said, "Despite many treatments being available for allergic rhinitis, Glenmark is excited to launch Ryaltris as the only first line combination inhaler treatment option for patients across Europe. Upwards of 25% of the population in Europe suffers from the debilitating symptoms of allergic rhinitis, so we hope that Ryaltris will bring some of these real benefits – a simple inhaler, offering fast and effective relief."

Glenmark has also partnered with Hikma Pharmaceuticals PLC and Bausch Health for the commercialisation of Ryaltris in the US and Canada respectively.

Ryaltris sales continue to progress well in Australia, after the successful launch in 2020 by Glenmark's partner, Seqirus Pty. Ltd.

Ryaltris was also recently launched in South Africa, Ukraine and Uzbekistan. So far, Glenmark has received approval for Ryaltris in Australia, South Korea, Cambodia, Ukraine, Uzbekistan, Namibia, Russia, South Africa, and Ecuador. Ryaltris is currently under regulatory review in Canada, Brazil, Malaysia, Saudi Arabia and several other markets. Glenmark's partner in China, Grand Pharmaceutical (China) Co. Ltd., plans to submit an IND in this financial year.